Here's the latest variant picture for New Zealand, to late January.

In a chaotic scene, NB.1.8.1 "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" are all significant.

BA.3.2.* "Cicada" is also present, but at only 11%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #Stratus
🧵

Here's the latest variant picture for New Zealand, to mid-January.

In a chaotic scene, NB.1.8.1 "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" are all significant.

BA.3.2.* "Cicada" is also present, but at only 8%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to early January.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus".

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to early December.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus".

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

This scenario raises the risk of rapid reinfections, for those relying on disease-acquired immunity.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to late November.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus".

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to mid-November.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus".

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to late October.

In a chaotic scene, NB.1.8.1 "Nimbus" is being challenged by JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus".

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to early October.

JN.1.* +DeFLuQE (led by PE.1.4) grew to 47%, taking over dominance.

NB.1.8.1 "Nimbus" fell to 32%.

XFG.* "Stratus" grew to 32%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to late September.

NB.1.8.1 "Nimbus" has continued to dominate, but fell sharply to finish at 38%.

JN.1.* +DeFLuQE grew slightly to 32%.

XFG.* "Stratus" grew strongly to 27%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to late September.

NB.1.8.1 "Nimbus" has continued to dominate, finishing down slightly to 52%.

JN.1.* +DeFLuQE finishing down at 23%.

XFG.* "Stratus" grew strongly to 21%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for New Zealand, to mid-September.

NB.1.8.1 "Nimbus" has continued to dominate, finishing roughly flat at 58%.

XFG.* "Stratus" grew strongly to 22%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE #XFG #Stratus
🧵

Here's the latest variant picture for Australia, to early September.

NB.1.8.1 "Nimbus" has continued to dominate, but fell back to finish at 46%.

It is under threat from the rebound in JN.1.* +DeFLuQE, which grew strongly to 39%.

#COVID19 #SARSCoV2 #Australia #NB_1_8_1 #Nimbus #DeFLuQE
🧵

Here's the latest variant picture for New Zealand, to early September.

NB.1.8.1 "Nimbus" has continued to dominate, finishing at 57%.

It looks under serious threat from JN.1.* +DeFLuQE, which finished at 36%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE
🧵

Here's the latest variant picture for Australia, to late August.

NB.1.8.1 "Nimbus" has continued to dominate, but fell back to finish at 47%.

It looks under threat from the rebound in JN.1.* +DeFLuQE, which grew to 32%.

#COVID19 #SARSCoV2 #Australia #NB_1_8_1 #Nimbus #DeFLuQE
🧵

Here's the latest variant picture for New Zealand, to the end of August.

NB.1.8.1 "Nimbus" has continued to dominate, but fell back to finish at 49%.

It looks under serious threat from JN.1.* +DeFLuQE, which rebounded to 34%.

#COVID19 #SARSCoV2 #NZ #NB_1_8_1 #Nimbus #DeFLuQE
🧵

Here's the latest variant picture for Australia, to late August.

NB.1.8.1 "Nimbus" has continued to dominate, but fell back to finish at 56%.

It looks under threat from the rebound in JN.1.* +DeFLuQE, growing strongly to 29%.

#COVID19 #SARSCoV2 #Australia #NB_1_8_1 #Nimbus #DeFLuQE
🧵

Here's the latest variant picture for New Zealand, to mid-May.

The NB.1.8.1 "Nimbus" variant has surged to dominance at 40% frequency.

The long reign of the DeFLuQE variants has indeed ended, collapsing to 19%.

#COVID19 #NZ #NB_1_8_1 #Nimbus #DeFLuQE
🧵

Here's the latest variant picture for New Zealand, to mid-May.

DeFLuQE variants continue to dominate at around 40-55%, but finally look under threat.

The XDV.* variant clan (driven by NB.1.8.1) grew to around 24%.

#COVID19 #NZ #DeFLuQE #XDV #NB_1_8_1
🧵

Here's the latest variant picture for New Zealand, to late April.

DeFLuQE variants continue to dominate at around 40-80%

The XDV.* variant - driven by it’s latest sub-lineage NB.1.8.1 – is present, but only up to 11% so far.

#COVID19 #NZ #DeFLuQE #XEC #NB_1_8_1
🧵

Here's the latest variant picture for New Zealand, to late April.

DeFLuQE variants continue to dominate at around 50-80%

The LP.8.1.* variant is not offering a sustained challenge.
#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand, to late March.

DeFLuQE variants continue to dominate at around 40-60%

The LP.8.1.* variant bubbled up to 22%, before falling back in more recent samples.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand, to mid-March.

DeFLuQE variants continue to dominate, with the LP.8.1.* variant up to 18%, competing with XEC.*.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, with the LP.8.1.* variant showing some strong recent growth to 24%, apparently overtaking XEC.*.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, with XEC.* struggling to break above 40%.

This is quite an unusual picture as XEC.* is already dominant in most places.

The LP.8.1.* variant has mostly been below 10%.

#COVID19 #NZ #DeFLuQE #XEC
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, with XEC.* seeming to be in decline.

This quite an unusual picture as XEC.* is already dominant in most places.

The LP.8.1.* variant grew to around 12%.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, although XEC.* is now challenging.

This quite an unusual picture as XEC.* is already dominant in most places.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, although XEC.* is now challenging.

This quite an unusual picture as XEC.* is already dominant in most places.

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

Here's the latest variant picture for New Zealand.

DeFLuQE variants continue to dominate, although XEC.* might be growing in recent samples.

The new LP.8.1.* group of variants is present, but is still at low frequency (around 5%).

#COVID19 #NZ #DeFLuQE #XEC #LP_8_1
🧵

A line graph showing the lineage frequency of the top 7 COVID-19 genomes in Ontario, Canada, up to December 10, 2024. The graph includes data from 4,928 sequenced genomes. The x-axis represents dates from October 27 to December 08, while the y-axis represents lineage frequency percentages from 0% to 35%. Different colored lines represent different genome lineages: KP.3.1.1 (blue), MC.1 (green), MC.13 (purple), MC.16 (pink), MC.24 (orange), XEC (brown), and XEC.8 (yellow). Below the main graph, there is a bar chart showing the number of samples (n) collected each day, ranging from 0 to 200 samples. The graph shows trends in the prevalence of each lineage over time, with KP.3.1.1 starting high and decreasing, while MC.13 increases and then stabilizes. Other lineages show more stable or fluctuating patterns.

#Variant update for #Ontario, #Canada (to Dec 10, 2024)

The KP.3.1.1 #DeFLuQE variant has finally been surpassed with XEC now in top place above 20% while the other 5 (MC.* and XEC.* descendants) remain < 7%. Graph tools by @mikehoney.bsky.social 🧪🧵1/